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Abstract 
Attempts to develop therapeutic vaccines against cervical cancer have been 
proven difficult . One of the major causes of  the failure is due to the use of the wrong 
mouse models based on transplantable tumours in testing the efficacy of vaccines. 
Now that a transgenic epithelial mouse model has been developed to closely mimic 
cervical cancer, the mechanisms needed to eliminate this type of cancer could be 
studied. The E7 oncoprotein of Human Papillomavirus (HPV) is the most expressed 
HPV protein in cervical cancers and its continuous production is essential to maintain 
the cancerous state and therefore the obvious target in the development of vaccines. 
Skin grafts expressing the HPV 16 E7 protein (E7 autografts) are not spontaneously 
rejected from an MHC matched immunocompetent host.  Interestingly, simultaneous 
placement of an MHC mismatched skin (allograft) next to an E7 autograft results in 
the E7 autograft rejection.  However when the allograft also expresses E7, the E7 
autograft is rejected more slowly.  Autograft rejection requires CD8+ T cells, and is 
accelerated by removal of CD4+ T cells after placement of the E7 expressing allograft, 
suggesting induction of an E7 specific CD4+ regulatory T cell population by the E7 
expressing allograft. This observation may have implications in designing effective 
vaccines and immunotherapy against cervical cancers in women. 
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 Introduction 
 
HPV infections, especially types HPV16 and HPV18, are the major cause of 
cervical cancers with more than 99% of observed tumours containing HPV DNA (1). 
Prophylactic vaccines against HPV are now available (2). However there is an urgent 
need to develop a therapeutic vaccine to cure women who already have cervical 
cancer, and to eradicate HPV-containing cancer/pre-cancer cells from the estimated 
10.5% of females worldwide who are already infected with the virus (3). Human 
cervical cancers produce the HPV-derived E7 oncoprotein whose continuous 
production is essential to maintain the cancerous state (4). Therefore the E7 
oncoprotein is a prime target for anti-cervical cancer therapeutic immunotherapies. In 
the past, anti-E7 vaccines were formulated based on data from E7-producing 
transplantable tumours in mouse models (5, 6, 7). However these vaccines failed 
when tested on cervical cancer patients (8, 9). One of the reasons that the attempts to 
develop a therapeutic vaccine against cervical cancer have failed in the past is due to 
the use of the wrong mouse model (E7 producing transplantable tumours) to test 
vaccine efficacy. The cause of this failure could be that cervical cancers are epithelial 
in origin and need a different type of an immune response to eliminate the cancer. 
To this end, a transgenic mouse model (K14E7) was developed previously in 
which keratinocytes express HPV-16 oncoprotein E7 under the control of the keratin-
14 promoter (10, 11). K14E7 skin grafted onto naïve, syngeneic, wild type mice was 
not spontaneously rejected in spite of an E7-specific humoral and cellular immune 
response promoted in graft recipients (11, 12). Furthermore, immunisation with 
vaccines that are known to reject E7 producing transplantable tumours, also failed to 
reject E7 skin grafts (11, 12). This result contrasts to similar skin-grafting experiments 
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where other proteins are used as transgenes, e.g, ovalbumin protein (OVA) & human 
growth hormone: such grafts spontaneously reject within 20 days (13, 14). These 
findings suggested that the fate of grafts is antigen dependant, and suggested the 
existence of a mechanism leading to E7 tolerance which could explain the failure of 
E7 therapeutic vaccination. 
 
Materials and Methods 
Mice. Specific pathogen-free FVB/N (H-2q) mice were obtained from the 
Animal Resources Centre (Perth, Australia). C57BL/6 (H-2b) wild-type mice, 
C57BL/6 and FVB/N mice transgenic for the HPV16 E7 oncoprotein driven from a 
K14 promoter were obtained from the Princess Alexandra Hospital Biological 
Resources Facility (Brisbane, Australia), where HPV16 E7 transgenic C57BL/6 mice 
were backcrossed with FVB/N mice to generate (K14E7.C57BL/6 x FVB/N) F1 mice. 
Description of these mice and of the transgene expression has been previously 
reported (10, 11). All mice were females between 6 and 12 weeks of age, and were 
maintained under specific pathogen-free conditions at the Princess Alexandra Hospital 
Biological Resources Facility.  
Skin Grafting.  An allograft [FVB/N x C57BL/6 (H-2qxb)] expressing E7 
from a keratin 14 promoter, or not expressing E7, was grafted adjacent to an autograft 
expressing E7 on FVB/N (H-2q) mice (Fig 1). Groups of 4 mice were grafted at a 
time, and the experiment was repeated two more times.  The results shown are pooled 
from the three experiments. Whole-thickness ear skin grafting was performed as 
previously described (12). Grafts vascularised and completely adherent seven days 
post-surgery were judged technically successful. Grafts were observed at least twice 
weekly for the duration of experiments. Grafts intact past 20 days after grafting were 
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considered healed.  Grafts intact at day 200 post-surgery were retained as non-
rejected. Skin graft rejection was assessed as described (14).  
CD4+ and CD8+ T Cell Depletion. CD4+ T cells were depleted using anti-
CD4 mAb (clone GK1.5) by i.p injections of 1.0 mg/mouse for each of three 
injections, two days apart. The first injection of Ab was given either 10 days before 
grafting, or 15 days after grafting. CD8+ T cells were depleted using 200µg/mouse of 
anti-CD8 mAb (clone 53-5.8) by i.p. injections at day 14 and day 2 before grafting. 
Depletion was checked using flow cytometry as previously described (15). More than 
95% of the cell population of interest was shown to be depleted (data not shown). 
Data Analysis.  All graphs were generated using GraphPad Prism version 5.01 
(La Jolla, CA 92037, USA), with the statistics calculated by using the Log rank test 
with a 95% confidence interval. Results were considered significant where the P value 
was ≤ 0.05.  
 
Results and Discussion  
Allo priming allows rejection of the HPV 16 E7 oncoprotein-producing syngeneic 
skin graft which is resistant to vaccination.  
MHC matched skin grafts expressing the HPV 16 E7 protein (E7 autograft) 
are not spontaneously rejected from an immunocompetent host (Fig 2A). However 
simultaneous placement of an allograft next to an E7 autograft results in the E7 
autograft rejection. The allografts were rejected in an average of 14 days or less as 
expected (data not shown), and induce an immune response which allows for the 
rejection of the E7-autograft in an average of 104 days (Fig. 2A).   
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CD8+ T cells are essential for E7 autograft rejection. 
When CD8+ cells are depleted before grafting, none of the E7 autografts are 
rejected (Fig. 2B), indicating that the presence of CD8+ T cells is essential during 
priming for the E7 autograft rejection process. A follow-up of E7 autografts up to 200 
days after grafting showed that there was no rejection. By this time the CD8+ 
population had recovered (16). Therefore the presence of unprimed CD8+ T cells is 
not sufficient for the rejection process.  
 
CD4+ T cells depletion hastens E7 autograft rejection. 
Next we determined the role of CD4+ T cells in the E7 autograft rejection.  
CD4+ T cells were depleted before grafting or 15 days after grafting. We wished to 
determine whether CD4+ T cells are directly involved in the graft rejection or 
providing help indirectly to CD8+ T cells to convert them to efficient killer cells. In 
contrast to our expectations, when the CD4+ T cells were depleted before grafting, the 
autograft rejection is accelerated compared to non-depleted control (average time of 
rejection 44 days vs 104 days after grafting, Fig 2C).  CD4+ T cells are therefore 
slowing the E7 autograft rejection. We hypothesize that a subtype of CD4+ T cell 
population (probably regulatory T cells or Treg) is suppressing the immune response 
driven by antigen specific CD8+ T cells. Others have observed that there are more 
CD4+Foxp3+ Treg cells in the E7 expressing skin compared with control mouse skin 
(17, and personal communication). Depleting CD4+ T cells may have impaired this 
suppressor function, and therefore amplified the response leading to graft rejection. A 
recent clinical study in which a synthetic long E7 and E6 peptide was used as a 
vaccine for women with cervical cancer showed that vaccinated women exhibited 
expanded levels of CD4+CD25+Foxp3+ Treg cell population (18).  These findings 
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agree with our data and suggest E7 inhibits induction of immunity to itself through a 
CD4+ (possibly CD25+ regulatory) T cell dependant mechanism. 
If CD4+ T cells are depleted after grafting, again the graft rejection process is 
hastened compared to the untreated mice. However the average time needed to reject 
the E7 autograft is slightly longer than when the CD4+ T cells are depleted before 
grafting (52.6 days vs 44 days, Fig 2C).  This may indicate that shorter duration of 
CD4+ T cell in contact with the E7 antigen in this case have induced lower amounts of 
suppressor T cells.  In the presence of the graft, CD4+ T cells may start to suppress the 
CD8+ T cell response. Once CD4+ T cells are depleted, the suppressive signal to CD8+ 
T cells may be switched off and the rejection process can take place. Another possible 
explanation is that some other lymphocyte populations such as CD8+ T cells or NK T 
cells expanded to fill in the vacuum created by CD4+ T cell depletion, and rejected the 
autografts more efficiently. Twenty days after grafting, we stopped anti-CD4 mAb 
injections, allowing CD4+ populations (including Tregs) to recover. It has been shown 
that more than 50% of the entire CD4+ T cell population depleted using our antibody 
regimen recovered 55 days post injection (16). This may explain why after 61 days, 
no more E7 autograft rejection is observed.  
  
Absence of E7 in the allograft promotes the fastest rejection rate for E7 Autografts. 
When the E7-autograft is grafted simultaneously with an allograft that does 
not produce E7, the rejection of the E7 autograft is quicker than observed with any of 
the other experiments (average time of rejection=27 days compared with the average 
of 104 days when the allograft is producing E7) (Fig 2D).  This observation indicates 
that the E7 protein in the allograft is also actively suppressing E7 autograft rejection 
by possibly promoting the generation of CD4+ Treg cells that will slow down the 
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rejection process of the E7 autograft. This correlates well with our data on CD4+ T 
cell depleted animals.  It is interesting to note that the depletion of CD4+ T cells either 
before or after grafting, hastened the mean time of rejection of the E7-autograft to 
about 40 days, similar to what is observed with the E7 negative allograft induced 
response. Thus we conclude that the induction of specific immunity to E7 was 
inhibited by the expression of E7 in the allograft, and the inhibition mechanism 
potentially involves CD4+ T cells.  Therefore the efficacy of allo priming as a means 
to induce tumour-specific immunity may depend on whether a simultaneous 
regulatory CD4+ T cells population was induced or not.  
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 Legends 
Fig. 1. Mouse Model 
A mouse model for cervical cancer was used in which E7-expressing skin 
(K14E7.FVB/N) is grafted onto wild-type FVB/N syngeneic recipient mice. Rejection 
of this E7-autograft was induced by the simultaneous co-grafting adjacent to the E7 
autograft, of an MHC-mismatched skin (K14E7.C57BL/6 x FVB/N)F1. We 
selectively depleted CD8+ (14 days before grafting) or CD4+ T cells (10 days before 
grafting or 15 days after grafting) to investigate the role of those T cell populations in 
the rejection of the E7-autograft. 
 
Fig. 2. 
Survival of E7 skin autografts on FVB/N mice. 
2A. FVB/N mice were grafted with E7.FVB/N skin (E7 Autograft) only (∆) or 
simultaneously co-grafted with (E7.C57BL/6 x FVB/N)F1 skin (E7 Allograft) (●).  
Kaplan-Meier analysis of survival of the E7 autograft was performed.  There was no 
rejection observed even after 200 days post-surgery in the group grafted only with E7-
autograft.  5 out of 12 mice from the double-grafted groups rejected the E7 autograft 
between day 90 and 125 post-surgery (Average 104 days) (statistically significant: 
Mantel-Cox test, p=0.013).  
2B.  FVB/N mice were simultaneously co-grafted with E7.FVB/N skin (E7 Autograft) 
and (E7.C57BL/6 x FVB/N)F1 skin (E7 Allograft). Graft recipients were untreated 
(●), or treated with anti-CD8 mAb (clone 53-5.8) day 14 and day 2 before grafting 
(∆). None of the CD8+ T cell depleted mice rejected the E7-autograft even 200 days 
post-surgery (p=0.013).   
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2C.   FVB/N mice were simultaneously co-grafted with E7.FVB/N skin (E7 
Autograft) and (E7.C57BL/6 x FVB/N)F1 skin (E7 Allograft).  Mice were untreated 
(●), or treated with anti-CD4 mAb (clone GK1.5) either 10, 8 and 6 days before 
grafting (∆), or 15, 17 and 19 days after grafting (▼).  Survival of E7 grafts of non-
depleted control versus group depleted before grafting: p=0.36; survival of E7 grafts 
of non-depleted control versus group depleted after grafting: p=0.51; survival of E7 
grafts of group depleted before grafting versus group depleted after grafting: p=0.11. 
2D. FVB/N mice were simultaneously co-grafted with E7.FVB/N skin (E7 Autograft) 
and either E7 positive or E7 negative (C57BL/6 x FVB/N)F1 allograft skin.  Graft 
survival percentage is shown for the E7 autografts when co-grafted with E7 negative 
allografts (∆) or E7 positive allografts (●). Median survival day = 27 (E7 negative 
group) vs 103 (E7 positive control), p=0.013. 
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 Figures 
Fig. 1. 
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